arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ligand Pharmaceuticals Incorporated

LGND Health Care Biotechnology: Pharmaceutical Preparations
$285.60
Today
as of Sep 4, 16:51 ET
Last 30 days -3.60% Jul 28 → Sep 04
$278.39 $284.88 $291.38 $297.87 $304.36 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$287.41
High
$289.71
Low
$285.47
Volume
$132,386
Avg Vol
$249,892
Mkt Cap
$5.8B
P/E (TTM)
39.50
Beta
—
52w High
$326.63
52w Low
$161.82
Div Yield
—
Shares Out
$20M

Recent Press Releases & News last 60 days · 24 items

Sep 4 · 10:44 Insider Monkey
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
Aug 26 · 17:02 MarketBeat
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Aug 26 · 11:00 PR GlobeNewswire
Ligand to Participate in September Investor Conferences
▸ Show all 24 press releases & news Free account →

Overview

52-week range
$162
$327
75% of range
Avg surprise (last 3)
-610.9%
Avg reaction (last 2)
-6.2%
0% positive
Latest IV / EM
33%
EM ±5.1% · $290 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.88$-0.74$1.40$3.54$5.68 Actual $2.33Actual $0.13Actual $-0.59Actual $4.75Actual $-2.88Actual $-0.39Actual $-2.21Est $0.14Actual $0.24Est $0.21Actual $5.68Actual $-0.67Est $0.98Actual $2.22 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-42M$-1M$40M$82M$123M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $2.22 — — — — financials
Thu May 7, 2026Mar/2026 $-0.67 $0.98 -168.4% +69.7% -9.6% earnings
Tue Sep 30, 2025Sep 2025 $5.68 — — — — financials
Thu Aug 7, 2025Jun/2025 $0.24 $0.21 +14.3% — — earnings
Thu May 8, 2025Mar/2025 $-2.21 $0.14 -1,679% — -2.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.39 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2.88 — — — — financials
Sun Mar 31, 2024Mar 2024 $4.75 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.59 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.13 — — — — financials
Fri Mar 31, 2023Mar 2023 $2.33 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$64M$52M—$115M$48M$45M—$52M
Cost of revenue————————
Gross profit————————
Operating income$9M$17M—$55M$8M$-36M—$3M
Net income$49M$-13M—$117M$5M$-42M—$-7M
EPS (diluted)$2.22$-0.67—$5.68$0.24$-2.21—$-0.39

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1.01B$115M$175M$139M$68M$48M$72M$64M
Inventory$10M$13M$9M$12M$15M$15M$14M$17M
Total current assets$1.46B$865M$832M$754M$353M$309M$332M$309M
Total assets$2.19B$1.53B$1.56B$1.48B$949M$905M$942M$955M
Long-term debt$1.13B———————
Total liabilities$1.22B$535M$543M$527M$120M$110M$111M$114M
Total equity$968M$997M$1.02B$950M$827M$796M$830M$841M

Implied volatility — last 90 days

32%42%51%61%70% Jun 07 — IV 48% · EM ±6.6%Jun 08 — IV 45% · EM ±5.9%Jun 09 — IV 47% · EM ±5.9%Jun 10 — IV 48% · EM ±5.7%Jun 11 — IV 50% · EM ±5.5%Jun 12 — IV 44% · EM ±4.5%Jun 15 — IV 54% · EM ±3.9%Jun 16 — IV 61% · EM ±3.6%Jun 17 — IV 68% · EM ±2.8%Jun 19 — IV 39% · EM ±8.5%Jun 22 — IV 46% · EM ±9.6%Jun 23 — IV 45% · EM ±9.2%Jun 24 — IV 44% · EM ±8.9%Jun 25 — IV 45% · EM ±8.9%Jun 26 — IV 44% · EM ±8.4%Jun 29 — IV 46% · EM ±8.1%Jun 30 — IV 43% · EM ±7.4%Jul 01 — IV 42% · EM ±7.0%Jul 02 — IV 42% · EM ±6.8%Jul 03 — IV 43% · EM ±6.8%Jul 06 — IV 45% · EM ±6.3%Jul 07 — IV 48% · EM ±6.3%Jul 08 — IV 49% · EM ±6.1%Jul 09 — IV 43% · EM ±5.1%Jul 10 — IV 41% · EM ±4.5%Jul 13 — IV 50% · EM ±4.2%Jul 14 — IV 47% · EM ±3.4%Jul 15 — IV 56% · EM ±3.3%Jul 16 — IV 65% · EM ±2.7%Jul 20 — IV 47% · EM ±11.2%Jul 21 — IV 47% · EM ±11.0%Jul 22 — IV 46% · EM ±10.5%Jul 23 — IV 46% · EM ±10.4%Jul 24 — IV 47% · EM ±10.4%Jul 27 — IV 49% · EM ±10.1%Jul 28 — IV 50% · EM ±10.2%Jul 29 — IV 49% · EM ±9.9%Jul 30 — IV 48% · EM ±9.5%Jul 31 — IV 48% · EM ±9.2%Aug 03 — IV 52% · EM ±9.2%Aug 04 — IV 52% · EM ±9.0%Aug 05 — IV 50% · EM ±8.4%Aug 06 — IV 42% · EM ±6.7%Aug 07 — IV 40% · EM ±6.2%Aug 10 — IV 41% · EM ±5.7%Aug 11 — IV 38% · EM ±5.0%Aug 12 — IV 38% · EM ±4.7%Aug 13 — IV 34% · EM ±4.0%Aug 14 — IV 37% · EM ±4.1%Aug 17 — IV 42% · EM ±3.5%Aug 18 — IV 42% · EM ±3.1%Aug 19 — IV 44% · EM ±2.6%Aug 20 — IV 71% · EM ±3.0%Aug 24 — IV 37% · EM ±7.7%Aug 25 — IV 37% · EM ±7.5%Aug 26 — IV 35% · EM ±7.0%Aug 27 — IV 36% · EM ±7.1%Aug 28 — IV 37% · EM ±7.0%Aug 31 — IV 36% · EM ±6.3%Sep 01 — IV 36% · EM ±6.2%Sep 02 — IV 35% · EM ±5.8%Sep 03 — IV 35% · EM ±5.6%Sep 04 — IV 33% · EM ±5.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in